Three monoclonal antibodies (MAbs), designated 7C5, 7C9, and 5G8, against a cytoplasmic antigen of Cryptococcus neoformans were produced. MAbs 7C5 and 7C9 recognize culture filtrate antigen (exoantigen) of both encapsulated and nonencapsulated isolates of this pathogen, which suggests that they do not recognize capsular polysaccharide material. This is supported by immunofluorescence data which show reactivity of all 3 MAbs to cytoplasm and cell membranes only. MAb 7C9 also recognized C. neoformans var Cryptococcus neoformans is an encapsulated yeast which causes the disease cryptococcosis usually characterized in its disseminated form by meningitis. The disease has become an important complication in human immunodeficiency virus (HIV) infection, particularly in Africa, where, for example, one recent survey in Zaire showed that 11% of AIDS patients had active infections, as indicated by the presence of circulating capsular antigen (19). Serodiagnosis relies on a latex agglutination test in which latex particles are coated with polyclonal antisera directed against capsular polysaccharide material (10, 17) . Although this has proved to be a useful test, it has a number of drawbacks, particularly with regard to false-positives generated either through the presence of rheumatoid factor or infection with the crossreactive pathogen Trichosporon beigelii (3, 5, 12). However, the major limitation of the test in AIDS patients is its detection of persistent high carbohydrate capsular antigen titers which may reflect failure to eliminate polysaccharide as well as the organisms themselves (4). This makes the test of lesser value in determining the outcome of the disease and the correct course of therapy. Therefore, there is a need for species-specific antibodies that recognize noncarbohydrate exoantigens for use in diagnosis and follow-up of the infection in AIDS patients.
Cryptococcus neoformans is an encapsulated yeast which causes the disease cryptococcosis usually characterized in its disseminated form by meningitis. The disease has become an important complication in human immunodeficiency virus (HIV) infection, particularly in Africa, where, for example, one recent survey in Zaire showed that 11% of AIDS patients had active infections, as indicated by the presence of circulating capsular antigen (19) . Serodiagnosis relies on a latex agglutination test in which latex particles are coated with polyclonal antisera directed against capsular polysaccharide material (10, 17) . Although this has proved to be a useful test, it has a number of drawbacks, particularly with regard to false-positives generated either through the presence of rheumatoid factor or infection with the crossreactive pathogen Trichosporon beigelii (3, 5, 12) . However, the major limitation of the test in AIDS patients is its detection of persistent high carbohydrate capsular antigen titers which may reflect failure to eliminate polysaccharide as well as the organisms themselves (4) . This makes the test of lesser value in determining the outcome of the disease and the correct course of therapy. Therefore, there is a need for species-specific antibodies that recognize noncarbohydrate exoantigens for use in diagnosis and follow-up of the infection in AIDS patients.
Although several groups have produced monoclonal antibodies (MAbs) against C. neoformans, they have all been directed against capsular carbohydrate (6, 7) . Recently our group has been able to produce highly specific MAbs against noncarbohydrate antigens of several fungal pathogens (9, 11) , using a modification of the technique of cyclophosphamide ablation of B-cell responses to common antigenic determinants (15) . Preliminary data on these MAbs suggest that they will be diagnostically useful. In this paper we line. MAbs were then assigned to subclasses, using the Serotec subclassing kit (Serotec, Kidlington, Oxford, United Kingdom); the MAbs were first bound to C. neoformans antigen (capsular positive) on microtiter plates and were then recognized by using the appropriate swine anti-mouse IgG subclass probe. The latter was in turn recognized by a peroxidase-linked donkey anti-swine IgG probe which was visualized using OPD as described above.
The MAbs were purified using a protein A-Sepharose column (Pharmacia, Milton Keynes, United Kingdom) (8) . Citric acid buffer (0.1 M; pH 6.0) was effective at eluting bound MAbs from the column. Protein determinations were carried out as detailed previously. Purified MAbs were then made up in PBS-Tween (initial concentration, 100 pug ml-'), and their specificity was assessed by ELISA (100 pil per well) when reacted with the different fungal cytoplasmic antigens described earlier (1 p,g per well). MAbs were also assessed for reactivity to C. neoformans culture supernatant (exoantigen) by ELISA at an initial antigen concentration of 1 pug per well, which was progressively diluted 1:10. Negative controls were provided by using either the species-specific anti-H. capsulatum MAb C69 (11) or PBS-Tween.
Polyacrylamide gel electrophoresis, electroblotting, and immunoenzyme development. Each fungal antigen preparation containing protease inhibitors (total of 100 ,ug per gel) was first boiled for 2 to 5 min with 2-mercaptoethanol and sodium dodecyl sulfate (SDS) and then electrophoresed in a Trisglycine-SDS running buffer using a mini Protean II cell (Bio-Rad, Hemel Hempstead, Hertfordshire, United Kingdom) on a 10% (wt/vol) polyacrylamide gel at 200 V for 1 h. Gibco BRL (Paisley, Scotland) molecular weight markers were run simultaneously after similar pretreatment. Separated antigens were then transferred onto nitrocellulose paper in a Tris-glycine buffer using a semidry multigel electroblotter ( encapsulated C. neoformans antigen, despite the fact that the mice had not been immunized with the former. This is illustrated in Fig. 1 , which shows the differential activity of the sera from the mouse chosen for the fusion. Control mice which did not receive cyclophosphamide treatment between immunizations with C. neoformans and T. beigelii antigens showed no differential activity by ELISA (data not shown). The initial screening of the fusion by ELISA revealed 15 wells that were reactive to both C. neoformans var. neoformans strains (capsule positive and negative), with little or no recognition of T. beigelii. From these, three MAbs were produced after successive subcloning and designated 7C9, 7C5, and 5G8; each was found to be of the IgGl subclass. When tested in an ELISA, 7C9 showed greatest recognition of the acapsular isolate of C. neoformans, with lower reactivity to the encapsulated C. neoformans var. neoformans and C. neoformans var. gattii isolates. There was no recognition of the T. beigelii antigens or any of the other fungal pathogens tested (Fig. 2) . In contrast, MAbs 7C5 and 5G8 showed highest reactivities to the encapsulated isolates of C. neoformans var. neoformans, with a lower value for the acapsular mutant. These MAbs showed some slight recognition of T. beigelii antigens, although there was no reactivity to C. neoformans var. gattii isolates or to any other fungal cytoplasmic antigens (Fig. 2) .
MAb 7C9 was reactive to the culture supernatants of both Cryptococcus variants, at a minimal protein concentration of approximately 1 pg, while 7C5 was reactive only to the C. neoformans variant at a minimal concentration of approximately 1 ng (Fig. 3) . MAb 7C9 exhibited a prozone effect in its reactivity to antigen. Compared with MAb C69 or PBSTween controls, MAb 5G8 exhibited no recognition of antigens.
Western blot analysis of both capsular and acapsular C. neoformans isolates as well as C. neoformans var. gattii and culture filtrate antigens showed that 7C9 recognized bands at 110 to 120, 65 to 70, 45 to 50, and 36 to 38 kDa (Fig. 4) , with no recognition of T. beigelii (on immunoblots) or of the other fungal pathogens (data not shown). Both 5G8 and 7C5 recognized a band at 36 to 38 kDa and a fainter band at approximately 30 kDa in blots of C. neoformans (encapsulated and nonencapsulated) and T. beigelii antigens. 7C5 also showed very faint reactivity to these bands when reacted Isolates of all other fungi tested gave values below 0.1 (data not shown).
with blots of culture filtrate antigen. There was again no recognition of other fungal antigens (data not shown).
Indirect immunofluorescence studies revealed that both 5G8 and 7C5 were strongly reactive to both the cytoplasm and cell membrane of the capsular and acapsular isolates of C. neoformans, with no staining of the cell wall or capsule. In contrast, 7C9 was poorly reactive but showed the same pattern of reactivity as the two other MAbs (Fig. 5) .
DISCUSSION
The successful production of three MAbs which show little or no cross-reaction with antigens other than those targeted extends the effectiveness of the cyclophosphamide modification of conventional immunization protocols which we had previously applied to the tropical dimorphic fungi (9, 11) . The choice of the acapsular mutant in the immunization protocol was intended to increase the chances of ensuring the maximum antibody responses to noncarbohydrate capsule antigens, but it also served to reduce possible problems due to immunosuppression arising from the use of capsular material as an immunogen (16) . Although most unencapsulated mutants have a thin layer of glucuronoxylomannan, this does not seem to have affected the outcome of the fusion. The choice of T. beigelii as the antigen to which the mouse immune response was ablated was designed to minimize the production of MAbs against epitopes shared with other fungal pathogens, and this rationale seems to have proved effective. It was somewhat surprising that the polyclonal antibody response of the mouse chosen for the fusion, and indeed the responses of the other animals which were not used, were greater against the antigen from encapsulated C. neoformans to which they had never been exposed than to the acapsular antigen used in the protocol. From this, it can only be assumed that the effect of the cyclophosphamide had been to select not only B-cell clones which produced antibodies reactive to nonimmunodominant epitopes (15) but also those producing antibodies reactive to epitopes which in terms of absolute concentration were more prevalent in the encapsulated isolates. The recognition of the nonencapsulated isolate of C. neoformans by the three MAbs strongly suggests that they are directed against noncapsular antigens, a view that is supported by the fluorescence studies which demonstrated that they were directed at a cytoplasmic constituent of C. neoformans. Their reactivity by this method has potential application in the detection of this pathogen in histological material, an area which is presently being investigated.
The Western blot data on these MAbs suggest that they may recognize different determinants on the same antigen; most obviously both the ELISA and Western blot data for 7C5 and 5G8 suggest that the same antigen is being recognized by these MAbs, and indeed the recognition of a common 36-to 38-kDa band tends to link all three MAbs.
The major potential of MAbs 7C9 and 7C5, which have been clearly shown to detect noncapsular material which is both present in the cytoplasm and also readily detectable in culture filtrate lies in the detection of the relevant antigen in sera or cerebrospinal fluid of HIV patients infected with C. neoformans, since the present latex agglutination test would appear to be of limited prognostic value in these individuals. It is envisaged that more sensitive tests such as a two-site ELISA (14) will be developed for laboratory testing of HIV-positive sera, to be used along with the existing latex agglutination test. Such a test would ideally be in the form of a complete supplied kit for routine testing. Work is presently in hand both to identify the antigen and to develop the best means of using MAbs 7C9 and 7C5 in serodiagnosis.
